Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection

AIDS

Volumn 17, Issue 7, 2003, Pages 1009-1016

  Phillips, Andrew N ^a   Youle, Michael S ^a   Lampe, Fiona ^a   Johnson, Margaret ^a   Sabin, Caroline A ^a   Cozzi Lepri, Alessandro ^a   Loveday, Clive ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alternating therapy; Mathematical model; Multidrug resistance; Replicative capacity; Resistance; Sequential therapy

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; DRUG COST; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIROGENESIS; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; MUTATION;

EID: 0038555662     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00009     Document Type: Article

References (51)

1. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
2. Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999, 13:951-956.
3. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000, 356:291-296.
4. Miller V, Staszewski S, Nisius G, Cozzi Lepri A, Sabin C, Phillips AN, et al. Risk of new AIDS diseases in people on triple therapy. Lancet 1999, 353:463.
5. Larder BA, Darby G, Richman DD. HIV with reduced susceptibility to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243:1731-1734.
6. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in HIV-1 infection. Nature 1995, 373:117-123.
7. McLean AR, Nowak MA. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 1992, 6:71-79.
8. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci U S A 1997, 94:6971-6976.
9. Phillips AN, Youle MS, Johnson M, Loveday C. Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 2001, 15:2211-2220.
10. Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc Natl Acad Sci U S A 2000, 267:835-843.
11. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
12. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: the transmission of drug resistant HIV. Nat Med 2001, 7:1016-1020.
13. Dykes C, Fox K, Lloyd A, Morse E, Demeter LM. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 2001, 285:193-203.
14. Este JA, Quinones-Mateu ME, Barretina J. Reduced fitness of HIV-1 that are resistant to CXCR4 antagonists due to alterations in gp120 function. Antiviral Ther 2001, 6 (Suppl. 1):18.
15. Lu J, Kuritzkes D. Impaired fitness of HIV-1 site-directed mutants resistant to T-20. Antiviral Ther 2001, 6 (Suppl. 1):18.
16. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2001, 75:318-322.
17. Devereux HL, Youle MS, Johnson M, Loveday C. Rapid decline in detectability of HIV-1 resistance mutations after stopping therapy. AIDS 1999, 13:F123-F127.
18. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier S, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001, 15:2189-2191.
19. Hance A.J, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001, 75:6410-6417.
20. Birk M, Svedhem V, Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001, 15:1359-1368.
21. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picardo J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000, 14:2857-2867.
22. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
23. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999, 13:2541-2546.
24. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13:2349-2359.
25. Berkhout B. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci 1999, 6:298-305.
26. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001, 14:23-28.
27. Eron JJ, Benoit SL, Jensek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
28. Ribeiro RM, Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy. Proc Natl Acad Sci U S A 2000, 97:7681-7686.
29. Kepler TB, Perelson AS. Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc Natl Acad Sci U S A 1998, 95:11514-11519.
30. Anderson RM, May RM. Infectious diseases in humans: dynamics and control. Oxford: Oxford University Press; 1991.
31. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999, 17:625-656.
32. Grossman Z, Feinberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc Natl Acad Sci U S A 1998, 95:6314-6319.
33. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-127.
34. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
35. Phillips AN, McLean AR, Loveday C, Tyrer M, Bofill M, Devereux H, et al. In vivo HIV-1 replicative capacity in early and advanced infection. AIDS 1999, 13:67-73.
36. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Khalil Zayat M, Marfil S, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 2000, 14:397-403.
37. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, www.hivatis.org Accessed: February 2001.
38. British HIV Association (BHIVA). Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001, 2:276-313.
39. Phillips AN, Miller V, Sabin C, Cozzi Lepri A, Klauke S, Bickel M, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naïve people. AIDS 2001, 15:2379-2384.
40. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001, 28:232-239.
41. Brook MG, Dale A, Tomlinson D, Waterworth C, Daniels D, Forster G. Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units. AIDS Patient Care 2001, 15:491-494.
42. DeGruttola V, Diz L, D'Aquila R, Holder D, Phillips A, Baxter M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000, 5:41-48.
43. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001, 358:1322-1327.
44. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society - USA panel. JAMA 2000, 283:2417-2426.
45. Perelson AS, Kirschner DE, De Boer RJ. Dynamics of HIV-1 infection of CD4 cells. Math Biosci 1993, 114:81-88.
46. Essunger P, Perelson A. Modelling HIV infection of CD4+ T cell subpopulations. J Theor Biol 1994, 170:367-391.
47. Phillips AN, McLean A, Johnson MA, Tyrer M, Emery V, Griffiths P, et al. HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management. J Med Virol 1997, 53:261-265.
48. Quattro Steering Committee. A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - the Quattro Trial. AIDS 1999, 13:2209-2217.
49. Frost SDW, Dumaurier M-J, Wain-Hobson S, Leigh Brown AJ. Genetic drift and within-host metapopulation dynamics of HIV-1 infection. Proc Natl Acad Sci U S A 2001, 98:6975-6980.
50. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995, 267:483-489.
51. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmocokinet 1999, 36:41-66.